Targeting Long Non-Coding RNA TTN-AS1 Suppresses Bladder Cancer Progression

Related Experiment Video

Updated: Oct 16, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Huiyuan Xiao1, Wen Huang1, Yanlei Li2

  • 1Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.

Frontiers in Genetics
|October 21, 2021
PubMed

Insights

Titin-antisense RNA1 (TTN-AS1) is an oncogene in bladder cancer (BC) that promotes proliferation and invasion. Targeting TTN-AS1 and its downstream activator, activating transcription factor 2 (ATF2), may offer new therapeutic strategies for BC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Bladder cancer (BC) remains a significant health concern with ongoing research into novel therapeutic targets.
  • Understanding the role of non-coding RNAs, such as titin-antisense RNA1 (TTN-AS1), is crucial for advancing BC treatment.
  • The interplay between TTN-AS1 and other molecular pathways, like activating transcription factor 2 (ATF2), warrants investigation in BC.

Purpose of the Study:

  • To investigate the biological and clinical significance of TTN-AS1 in bladder cancer.
  • To determine the association between TTN-AS1 expression and patient prognosis in BC.
  • To elucidate the relationship between TTN-AS1 and activating transcription factor 2 (ATF2) in the context of BC.

Main Methods:

  • Kaplan-Meier analysis of TCGA and institutional data to correlate TTN-AS1 expression with BC prognosis.
  • Quantitative real-time PCR (RT-PCR) to compare TTN-AS1 levels in patients undergoing different surgical procedures (TURBT vs. Re-TURBT).
  • In vitro assays (MTT, colony formation, Transwell) to assess the impact of TTN-AS1 on BC cell proliferation and invasion.
  • Bioinformatic analysis and immunohistochemistry to explore the TTN-AS1 and ATF2 interaction.

Main Results:

  • Elevated TTN-AS1 expression is linked to poorer disease-free survival (DFS) in bladder cancer patients.
  • Higher TTN-AS1 levels were observed in BC patients who underwent re-transurethral resection of bladder tumor (Re-TURBT) compared to TURBT.
  • Silencing TTN-AS1 significantly inhibited the proliferation and invasion capabilities of BC cell lines.
  • ATF2 identified as a potential downstream target of TTN-AS1, with its high expression also correlating with adverse DFS.

Conclusions:

  • TTN-AS1 functions as an oncogene in bladder cancer, exerting its effects partly through the activation of ATF2.
  • TTN-AS1 and its pathway represent a promising novel therapeutic target for bladder cancer treatment.
  • Further research into TTN-AS1-targeted therapies could improve outcomes for BC patients.
Keywords:
bioinformacticsbladder cancerlong non-coding RNAoncogeneprognosis

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K